Martin Lehr
Mr. Lehr is the Co-founder and CEO of Context Therapeutics. In addition, Mr. Lehr is a member of the Scientific Advisory Board of Integral Molecular, an antibody discovery company. Previously, Martin was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research institutions. At Osage, Martin focused on early stage oncology and rare disease opportunities. Prior to Osage, Martin conducted research at the Sloan Kettering Institute in DNA repair and at the Children’s Hospital of Philadelphia in thrombosis and hemostasis. In addition to his role at Context, Martin is a Director of BioBreak, a biotech executive peer group with over 2,500 active members across the United States. He holds an M.A. in Biotechnology from Columbia University and a B.A. in Economics from the University of Pennsylvania.
